287 related articles for article (PubMed ID: 32774474)
1. Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Liu T; Jin B; Chen J; Wang H; Lin S; Dang J; Li G
Ther Adv Med Oncol; 2020; 12():1758835920940927. PubMed ID: 32774474
[TBL] [Abstract][Full Text] [Related]
2. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
3. Severe immune-related adverse events of immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.
Gu J; Shi L; Jiang X; Wen J; Zheng X; Cai H; Zhang W
Cancer Immunol Immunother; 2022 Sep; 71(9):2239-2254. PubMed ID: 35124713
[TBL] [Abstract][Full Text] [Related]
4. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Chai QQ; Du JY; Zhu J; Wu B
Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
[No Abstract] [Full Text] [Related]
5. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
Zheng J; Huang B; Xiao L; Wu M; Li J
Front Oncol; 2022; 12():821626. PubMed ID: 36568203
[TBL] [Abstract][Full Text] [Related]
6. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Zhang W; Gu J; Bian C; Huang G
Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
[No Abstract] [Full Text] [Related]
7. Comparative safety of immune checkpoint inhibitors and chemotherapy in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Chen CY; Huang CH; Chen WC; Huang MS; Wei YF
Int Immunopharmacol; 2022 Jul; 108():108848. PubMed ID: 35597121
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
10. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
[TBL] [Abstract][Full Text] [Related]
11. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
Mei T; Wang T; Deng Q; Gong Y
Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
[TBL] [Abstract][Full Text] [Related]
12. Deaths and adverse events from adjuvant therapy with immune checkpoint inhibitors in solid malignant tumors: A systematic review and network meta-analysis.
Xie R; Wu J; Shang B; Bi X; Cao C; Guan Y; Shi H; Shou J
Cancer Innov; 2022 Dec; 1(4):293-304. PubMed ID: 38089086
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis.
Peng TR; Lin HH; Tsai FP; Wu TW
Thorac Cancer; 2021 Nov; 12(21):2873-2885. PubMed ID: 34545685
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis.
Konwar M; Bose D; Maurya M; Ravi R
J Oncol Pharm Pract; 2023 Apr; 29(3):557-576. PubMed ID: 35147454
[TBL] [Abstract][Full Text] [Related]
15. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
16. Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis.
Hong B; Du B; Chen R; Zheng C; Ni R; Liu M; Yang J
BMC Med; 2024 Feb; 22(1):75. PubMed ID: 38373990
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.
Wang S; Yan L; Yu J; Lu C
Eur Arch Otorhinolaryngol; 2024 Feb; ():. PubMed ID: 38358507
[TBL] [Abstract][Full Text] [Related]
18. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
Du J; Wang X; Fan L; Shan X; Li M; Liu L
Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Network Meta-Analysis of Immune Checkpoint Inhibitors in Combination with Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Carcinoma.
Chen HL; Tu YK; Chang HM; Lee TH; Wu KL; Tsai YC; Lee MH; Yang CJ; Hung JY; Chong IW
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]